Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2016

Karl Hecker's Biography



Karl Hecker, Vice President of Product Development, Rubicon Genomics, Inc.

Karl Hecker joined Rubicon Genomics in October of 2014 bringing over 25 years of scientific experience in chemistry and molecular biology and more than 15 years of industry product development experience. He held positions of increasing importance in several companies including HTG Molecular Diagnostics, Quidel Corporation, Perkin Elmer Life and Analytical Sciences and Invitrogen Corporation. He holds M.S. degrees from Eastern Illinois University and Johann Wolfgang Goethe University and earned a Ph.D. from Florida State University before completing postdoctoral research at Florida State University and Harvard Medical School.

Karl Hecker Image

NGS Libraries From Cell-free DNA Containing Molecular Tags Prepared with ThruPLEX® Technology Improve Ability to Detect Rare Alleles

Thursday, 29 September 2016 at 11:00

Add to Calendar ▼2016-09-29 11:00:002016-09-29 12:00:00Europe/LondonNGS Libraries From Cell-free DNA Containing Molecular Tags Prepared with ThruPLEX® Technology Improve Ability to Detect Rare AllelesLiquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

Next Generation Sequencing (NGS) of cell-free DNA (cfDNA) enables non-invasive access to genetic information from liquid biopsies. Key to identifying rare genetic mutations is improved sequencing accuracy and the ability to distinguish between biological and PCR duplicates. Rubicon Genomics’ ThruPLEX Plasma-seq was developed specifically for cell-free DNA.


Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2016Liquid Biopsies and Minimally-Invasive Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com